ChemBriefNovartis investors turn spotlight on M&A after trial setbacks
Novartis shares dropped 11% following a late-stage trial failure for drug del-desiran, sparking investor concerns over its M&A strategy and $12 billion Avidity acquisition amid patent expiry challenge
reuters · 2026-09-10 22:02 UTC